Overactive bladder in menopausal women – estimate treatment of antimuscarinic drugs

Tomasz Pertyński; Agnieszka Wilamowska

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2007
vol. 6

Send email

Copy url:

abstract:

Overactive bladder in menopausal women – estimate treatment of antimuscarinic drugs

Tomasz Pertyński

,

Agnieszka Wilamowska

Przegląd Menopauzalny 2007; 3: 145–149

Online publish date: 2007/07/17

View full text Get citation

Urinary incontinence is estimated to affect over 5% of the adult population. It is defined by WHO as one of greatest medical problems of the 21st century. Urinary incontinence affects approximately 50 million adults in Europe and the United States. Overactive bladder (OAB syndrome) is defined by the International Continence Society as urgency, with or without urge incontinence, usually with frequency and nocturia. OAB affects approximately 50 million adults in Europe and the United States, with prevalence increasing with age. Current therapy consists primarily of anticholinergic drugs. Muscarinic receptor antagonists such as tolterodine, oxybutynin, trospine, solifenacin and darifenacin are the mainstay of treatment for OAB. Muscarinic receptor antagonists have varying efficacy, safety, tolerability and side effects. The aim of this study is to present the current knowledge and opinions on pharmacological treatment of OAB in the menopausal period.

keywords:

Overactive bladder in menopausal women – estimate treatment of antimuscarinic drugs

Tomasz Pertyński , Agnieszka Wilamowska

overactive bladder, treatment, antimuscarinic agents

Tomasz Pertyński

,

Agnieszka Wilamowska